Project Orbis

Monoclonal antibody
#Bristol Myers Squibb #Melanoma #MHRA #Monoclonal antibodies #Project Orbis

Nivolumab-relatlimab combination for melanoma approved in UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s advanced melanoma drug Opdualag (nivolumab-relatlimab) for patients from the age of 12. Opdualag was authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada,… Read More

#News #Regulatory